Follow The Filings

DTIL Precision BioSciences

Precision BioSciences earnings company data as of 7:49 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 2 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by DTIL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DTIL insider trades
  • $63K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Stanley Frankel Director
    Buy
    $6,000 1,000 shares at $6.00 +2.5% to stake
    Traded Sep 28 Filed Sep 30
  2. Melinda Brown Director
    Buy
    $7,116 1,135 shares at $6.27 +2.6% to stake
    Traded Sep 25 Filed Sep 29
  3. Geno J Germano Director
    Buy
    $16K 2,609 shares at $6.28 +5.8% to stake
    Traded Sep 25 Filed Sep 29
  4. Geno J Germano Director
    Buy
    $14K 3,000 shares at $4.72 +14% to stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
  5. Stanley Frankel Director
    Buy
    $13K 2,700 shares at $4.70 +16% to stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
  6. Melinda Brown Director
    Buy
    $6,864 1,381 shares at $4.97 +6.3% to stake
    Traded Dec 15, 2025 Filed Dec 17, 2025

Also filed in the last 12 months, not counted as buying or selling: 24 option exercises and 11 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
8-K 7.01,8.01,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
8-K 5.02,7.01,9.01
SCHEDULE 13G —
8-K 7.01,8.01,9.01
8-K 1.01,2.03,9.01
8-K 7.01,8.01,9.01
8-K 5.02,5.03,5.07,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
DEF 14A
DEFA14A
8-K 7.01,9.01
8-K 2.02,9.01
10-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.